Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile

References

• Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin. 2018;39(7):1176–1188.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Purrello F, Tsioufis C, et al. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opin Pharmacother. 2017;18:1243–1260.
   PubMed Web of Science ®Google Scholar
• Norhammar A, Bodegård J, Nyström T, et al. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. Diabetologia. 2016;59:1692–1701.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP. Management of patients with type 2 diabetes mellitus and acute coronary syndrome: better be safe than sorry! J Diabetes Complications. 2019;33:465–467.
   PubMed Web of Science ®Google Scholar
• Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2018;379(7):633–644.
   PubMed Web of Science ®Google Scholar
• Fox C, Golden S, Anderson C, et al. Update on prevention of cardiovascular disease in adults with Type 2 diabetes mellitus in light of recent evidence: a scientific statement from the american heart association and the american diabetes association. Diabetes Care. 2015;38(9):1777–1803.
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–2051.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Holman R. The UKPDS: implications for the dyslipidaemic patient. Acta Diabetol. 2001;38:S9–S14.
   PubMed Web of Science ®Google Scholar
• Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:1–19.
   Google Scholar
• Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27:130–139.
   PubMed Web of Science ®Google Scholar
• Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3:e001986.
   PubMed Web of Science ®Google Scholar
• Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110:26–37.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15:737–749.
   PubMed Web of Science ®Google Scholar
• Sattar N, McLaren J, Kristensen S, et al. Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59(7):1573–1574.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2016;39(Suppl 1):S60–71.
   PubMedGoogle Scholar
• Erion D, Park H, Lee H. The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Rep. 2016;49(3):139–148.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis D. Excessive “orthotopic” fat accumulation: links with cardiometabolic diseases and potential drug treatment. J Cell Physiol. 2020;235(9):6321–6322.
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet. 2010;376(9739):431–439.
   PubMed Web of Science ®Google Scholar
• Frías J, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004–1016.
   PubMed Web of Science ®Google Scholar
• Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care. 2013;36(5):1368–1376.
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomized trial. Lancet Diabetes Endocrinol. 2014;2(6):464–473.
   PubMed Web of Science ®Google Scholar
• Chiquette E, Toth PP, Ramirez G, et al. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag. 2012;8:621–629.
   PubMedGoogle Scholar
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–258.
   PubMed Web of Science ®Google Scholar
• Henry RR, Klein EJ, Han J, et al. Efficacy and tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes: an uncontrolled open-label extension of the DURATION-1 study. Diabetes Technol Ther. 2016;18(11):677–686.
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33(6):1255–1261.
   PubMed Web of Science ®Google Scholar
• Luo Y, Lu K, Liu G, et al. The effects of novel antidiabetic drugs on albuminuria in Type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2018;38(12):1089–1108.
   PubMed Web of Science ®Google Scholar
• Nauck M. Incretin-based therapies for Type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1):S3–18.
   PubMed Web of Science ®Google Scholar
• Mirani M, Favacchio G, Serone E, et al. Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort. Pharmacol Res. 2018;137:270–279.
   PubMed Web of Science ®Google Scholar
• Buse J, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomized, open-label study. Lancet. 2013;381(9861):117–124.
   PubMed Web of Science ®Google Scholar
• Buse J, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.
   PubMed Web of Science ®Google Scholar
• Du Q, Wang Y, Yang S, et al. Liraglutide for the treatment of Type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Adv Ther. 2014;31(11):1182–1195.
   PubMed Web of Science ®Google Scholar
• Liu W, Yu J, Tian T, et al., Meta‑analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy. Exp Ther Med. 2019;18(1): 342–351.
   PubMed Web of Science ®Google Scholar
• Zhao X, Huang K, Zheng M, et al. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMC Endocr Disord. 2019;19:1.
   PubMed Web of Science ®Google Scholar
• Fisher M, Petrie M, Ambery P, et al. Cardiovascular safety of albiglutide in the harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3(9):697–703.
   PubMed Web of Science ®Google Scholar
• Hernandez A, Green J, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomized placebo-controlled trial. Lancet. 2018;392(10157):1519–1529.
   PubMed Web of Science ®Google Scholar
• Tanzeum WF (albiglutide). Discontinued - FDA warns: anaphylaxis reaction [Internet]. TruLaw; 2020. Available from: https://trulaw.com/fda/tanzeum-albiglutide-anaphylaxis-reaction.
   Google Scholar
• Grunberger G, Chang A, Garcia Soria G, et al. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29(10):1260–1267.
   PubMed Web of Science ®Google Scholar
• Nauck M, Weinstock R, Umpierrez G, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in Type 2 diabetes in a randomized controlled Trial (AWARD-5). Diabetes Care. 2014;37(8):2149–2158.
   PubMed Web of Science ®Google Scholar
• Tuttle K, Lakshmanan M, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605–617.
   PubMed Web of Science ®Google Scholar
• Pfeffer M, Claggett B, Diaz R, et al. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Shaunik A, Liu M, et al. Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial. Diabetes Obes Metab. 2019;21(12):2712–2717.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomized trial. Lancet Diabetes Endocrinol. 2017;5(5):341–354.
   PubMed Web of Science ®Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258–266.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–2301.
   PubMed Web of Science ®Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomized, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251–260.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286.
   PubMed Web of Science ®Google Scholar
• Hjerpsted J, Flint A, Brooks A, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2017;20(3):610–619.
   PubMed Web of Science ®Google Scholar
• Avgerinos I, Michailidis T, Liakos A, et al. Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis. Diabetes Obes Metab. 2019;22(3):335–345.
   PubMed Web of Science ®Google Scholar
• Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–993.
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294–303.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. 2011;44:375–393.
   PubMed Web of Science ®Google Scholar
• Storgaard H, Gluud L, Bennett C, et al. Benefits and Harms of sodium-glucose co-transporter 2 inhibitors in patients with Type 2 diabetes: a systematic review and meta-analysis. Plos One. 2016;11:e0166125.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu Q, Chen Y, et al. Cardiovascular safety, long‐term noncardiovascular safety, and efficacy of sodium–glucose cotransporter 2 inhibitors in patients with Type 2 diabetes mellitus: a systemic review and meta‐analysis with trial sequential analysis. J Am Heart Assoc. 2018;7(2):e007165.
   PubMed Web of Science ®Google Scholar
• Li J, Shao YH, Wang XG, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. Endocr J. 2018;65:335–344.
   PubMed Web of Science ®Google Scholar
• Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, et al. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opin Drug Metab Toxicol. 2018;1–9. DOI:10.1080/17425255.2018.1541348
   Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9:533–571.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9:531–532.
   PubMed Web of Science ®Google Scholar
• Baker W, Buckley L, Kelly M, et al. Effects of sodium‐glucose cotransporter 2 inhibitors on 24‐hour ambulatory blood pressure: a systematic review and meta‐analysis. Am Heart J. 2017;6(5):e005686.
   Web of Science ®Google Scholar
• Weber M, Mansfield T, Alessi F, et al. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade. Blood Press. 2015;25(2):93–103.
   PubMed Web of Science ®Google Scholar
• Fadini G, Bonora B, Zatti G, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16(1):42.
   PubMedGoogle Scholar
• Sjöström C, Johansson P, Ptaszynska A, et al. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diabetes Vasc Dis Re. 2015;12(5):352–358.
   PubMed Web of Science ®Google Scholar
• Wiviott S, Raz I, Bonaca M, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Cefalu W, Stenlöf K, Leiter L, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183–1187.
   PubMed Web of Science ®Google Scholar
• Kario K, Hoshide S, Okawara Y, et al. Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: the SHIFT-J study. J Clin Hypertens. 2018;20(10):1527–1535.
   Web of Science ®Google Scholar
• Usiskin K, Kline I, Fung A, et al. Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results. Postgrad Med. 2014;126:16–34.
   PubMed Web of Science ®Google Scholar
• Weir M, Januszewicz A, Gilbert R, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens. 2014;16(12):875–882.
   PubMed Web of Science ®Google Scholar
• Mancia G, Cannon C, Tikkanen I, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016;68(6):1355–1364.
   PubMed Web of Science ®Google Scholar
• Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2014;38(3):420–428.
   PubMed Web of Science ®Google Scholar
• Chilton R, Tikkanen I, Hehnke U, et al. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2017;19(11):1620–1624. .
   PubMed Web of Science ®Google Scholar
• Özçelik S. The effect of low and high dose empagliflozin on HbA1c and lipid profile in Type 2 diabetes mellitus: A real world data. North Clin Istanb. 2020;7(2):167–173.
   PubMed Web of Science ®Google Scholar
• Liu J, Pong A, Gallo S, et al. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovasc Diabetol. 2019;18(1):59.
   PubMedGoogle Scholar
• Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Budoff M, Wilding J. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. Int J Clin Pract. 2017;71(5):e12948.
   Web of Science ®Google Scholar
• Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Prac. 2019;150: 8–16.
   PubMed Web of Science ®Google Scholar
• Bethel M, Patel R, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–113.
   PubMed Web of Science ®Google Scholar
• Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2013;27(1):130–139.
   PubMed Web of Science ®Google Scholar
• Golpon HA, Puechner A, Welte T, et al. Vasorelaxant effect of glucagon-like peptide-(7–36) amide and amylin on the pulmonary circulation of the rat. Regul Pept. 2001;102:81–86.
   PubMedGoogle Scholar
• Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21:1125–1135.
   PubMed Web of Science ®Google Scholar
• Erdogdu O, Nathanson D, Sjoholm A, et al. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through enos-, pka- and pi3k/akt-dependent pathways and requires glp-1 receptor. Mol Cell Endocrinol. 2010;325:26–35.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849–870.
   PubMed Web of Science ®Google Scholar
• Schwartz EA, Koska J, Mullin MP, et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 2010;212:217–222.
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 expert panel statement, main text. Curr Vasc Pharmacol. 2019;17(5):498–514.
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 expert panel statement, narrative review. Curr Vasc Pharmacol. 2019;17(5):515–537.
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profiles: executive summary of a 2019 expert panel statement. Curr Vasc Pharmacol. 2019;17(5):538–540.
   PubMed Web of Science ®Google Scholar
• Xiao C, Bandsma RH, Dash S, et al. Exenatide, a glucagon-like peptide receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol. 2012;32:1513–1519.
   PubMed Web of Science ®Google Scholar
• Verma S, Leiter L, Mazer C, et al. Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use. Circulation. 2018;138(15):1605–1607.
   PubMed Web of Science ®Google Scholar
• Nozue T, Yamada M, Tsunoda T, et al. Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Heart Vessels. 2015;31(8):1239–1246. .
   PubMed Web of Science ®Google Scholar
• Li R, Shan Y, Gao L, et al. The Glp-1 analog liraglutide protects against angiotensin ii and pressure overload-induced cardiac hypertrophy via PI3K/Akt1 and AMPKa signaling. Front Pharmacol. 2019;10:537.
   PubMed Web of Science ®Google Scholar
• Margulies K, Hernandez A, Redfield M, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction. JAMA. 2016;316(5):500.
   PubMed Web of Science ®Google Scholar
• Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomized, placebo-controlled trial. Eur J Heart Fail. 2017;19:69–77.
   PubMed Web of Science ®Google Scholar
• Lorenz M, Lawson F, Owens D, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16(1):6.
   PubMed Web of Science ®Google Scholar
• Goodwill A, Mather K, Conteh A, et al. Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev Endocr Metab Disord. 2014;15(3):209–217.
   PubMed Web of Science ®Google Scholar
• McMurray J, Solomon S, Inzucchi S, et al., Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 381(21): 1995–2008. 2019.
   PubMed Web of Science ®Google Scholar
• Matsumura K, Sugiura T. Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review. Cardiovasc Ultrasound. 2019;17(1):26.
   PubMed Web of Science ®Google Scholar
• Dunlay S, Weston S, Jacobsen S, et al. Risk factors for heart failure: a population-based case-control study. Am J Med. 2009;122(11):1023–1028.
   PubMed Web of Science ®Google Scholar
• Katholi R, Couri D. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens. 2011;2011:1–10.
   Google Scholar
• Verma S, Mazer C, Yan A, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2019;140(21):1693–1702.
   PubMed Web of Science ®Google Scholar
• Oliva R, Bakris G. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330–339.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP. Iron absorption, bone marrow fat and hematopoiesis in heart failure: additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)? J Diabetes Complications. 2019;33(11):107408.
   PubMed Web of Science ®Google Scholar
• Cavaiola TS, Pettus J. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. Diabetes Metab Syndr Obes. 2018;11:133–148.
   PubMed Web of Science ®Google Scholar
• Striepe K, Jumar A, Ott C, et al. Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus. Circulation. 2017;136(12):1167–1169.
   PubMed Web of Science ®Google Scholar
• Kang S, Verma S, Hassanabad A, et al., Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results. Can J Cardiol. 2020;36(4): 543–553.
   PubMed Web of Science ®Google Scholar
• Packer M. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab. 2018;20(6):1361–1366.
   PubMed Web of Science ®Google Scholar
• Bonora B, Avogaro A, Fadini G. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence. Diabet Metab Synd Ob. 2020;13: 161–174.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Mann JF, Schumacher H, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol. 2011;22:1353–1364.
   PubMed Web of Science ®Google Scholar
• Shuvy M, Zwas D, Lotan C, et al. Albuminuria: associated with heart failure severity and impaired clinical outcomes. Can J Cardiol. 2020;36(4):527–534.
   PubMed Web of Science ®Google Scholar
• Arques S, Ambrosi P. Human serum albumin in the clinical syndrome of heart failure. J Card Fail. 2011;17:451–458.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(2):S127–138.
   PubMedGoogle Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes;2008 December. Available from: https://www.fda.gov/downloads/Drugs/Guidances/
   Google Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(1):98–110.
   PubMedGoogle Scholar
• Drucker D. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30.
   PubMed Web of Science ®Google Scholar
• Sposito A, Berwanger O, de Carvalho L, et al., GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 17(1): 157. 2018.
   PubMedGoogle Scholar
• Bertoccini L, Baroni M. GLP-1 receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new insights and opportunities for cardiovascular protection. Adv Exp Med Biol. 2020. Online ahead of print. DOI:10.1007/5584_2020_494
   PubMedGoogle Scholar
• Nolen-Doerr E, Stockman M, Rizo I. Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity. Curr Obes Rep. 2019;8(3):284–291.
   PubMed Web of Science ®Google Scholar
• Hupfeld C, Mudaliar S. Navigating the “MACE” in cardiovascular outcomes trials and decoding the relevance of atherosclerotic cardiovascular disease benefits versus heart failure benefits. Diabetes Obes Metab. 2019;21(8):1780–1789.
   PubMed Web of Science ®Google Scholar
• Heuvelman V, Van Raalte D, Smits M. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res. 2019;116(5):916–930.
   Web of Science ®Google Scholar
• Sun F, Wu S, Wang J, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37(1):225–241.
   PubMed Web of Science ®Google Scholar
• Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (glp-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010;53:2256–2263.
   PubMed Web of Science ®Google Scholar
• Nystrom T, Gonon AT, Sjoholm A, et al. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125:173–177.
   PubMed Web of Science ®Google Scholar
• Wanner C, Lachin J, Inzucchi S, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137(2):119–129. .
   PubMed Web of Science ®Google Scholar
• Verma S, McMurray J, Cherney D. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol. 2017;2(9):939.
   PubMed Web of Science ®Google Scholar
• Sattar N, McLaren J, Kristensen S, et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59(7):1333–1339.
   PubMed Web of Science ®Google Scholar
• Cherney D, Perkins B, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13(1):28.
   PubMed Web of Science ®Google Scholar
• Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13(2):119–126.
   PubMed Web of Science ®Google Scholar
• Cheeseman C. Solute carrier family 2, member 9 and uric acid homeostasis. Curr Opin Nephrol Hypertens. 2009;18(5):428–432.
   PubMed Web of Science ®Google Scholar
• Newman J, Vani A, Aleman J, et al. The changing landscape of diabetes therapy for cardiovascular risk reduction. J Am Coll Cardiol. 2018;72(15):1856–1869.
   PubMed Web of Science ®Google Scholar
• Muzurović E, Dragnić S, Medenica S, et al. Weight-centric pharmacological management of type 2 diabetes mellitus – an essential component of cardiovascular disease prevention. J Diabetes Complications. 2020;34(8):107619.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Delanaye P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab. 2017;43(2):99–109.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr Cardiol Rep. 2019;21(8):70.
   PubMed Web of Science ®Google Scholar